Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 556

1.

YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT.

Kosnopfel C, Sinnberg T, Sauer B, Busch C, Niessner H, Schmitt A, Forchhammer S, Grimmel C, Mertens PR, Hailfinger S, Dunn SE, Garbe C, Schittek B.

Mol Cancer Res. 2018 May 9. doi: 10.1158/1541-7786.MCR-17-0528. [Epub ahead of print]

PMID:
29743296
2.

Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells.

Sinnberg T, Niessner H, Levesque MP, Dettweiler C, Garbe C, Busch C.

Biol Open. 2018 May 1. pii: bio.032656. doi: 10.1242/bio.032656. [Epub ahead of print]

3.

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21.

PMID:
29573941
4.

Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: Results of a prospective multicentre clinical study in 476 pigmented lesions.

Forschner A, Keim U, Hofmann M, Spänkuch I, Lomberg D, Weide B, Tampouri I, Eigentler T, Fink C, Garbe C, Haenssle HA.

Br J Dermatol. 2018 Mar 22. doi: 10.1111/bjd.16565. [Epub ahead of print]

PMID:
29569229
5.

The iris signal: blue periphery, tan collaret and freckles pattern - strong indicators for epidermal skin cancer in South-Eastern Europe.

Grigore M, Furtunescu F, Minca D, Costache M, Garbe C, Simionescu O.

J Eur Acad Dermatol Venereol. 2018 Mar 10. doi: 10.1111/jdv.14929. [Epub ahead of print]

PMID:
29524265
6.

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.

Sinnberg T, Levesque MP, Krochmann J, Cheng PF, Ikenberg K, Meraz-Torres F, Niessner H, Garbe C, Busch C.

Mol Cancer. 2018 Feb 17;17(1):59. doi: 10.1186/s12943-018-0773-5.

7.

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.

Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A.

Br J Cancer. 2018 Mar 20;118(6):777-784. doi: 10.1038/bjc.2017.488. Epub 2018 Feb 13.

8.

Pediatric patients with cutaneous melanoma: A European study.

Brecht IB, De Paoli A, Bisogno G, Orbach D, Schneider DT, Leiter U, Offenmueller S, Cecchetto G, Godzinski J, Bien E, Stachowicz-Stencel T, Ben-Ami T, Chiaravalli S, Maurichi A, De Salvo GL, Sorbara S, Bodemer C, Garbe C, Reguerre Y, Ferrari A.

Pediatr Blood Cancer. 2018 Jun;65(6):e26974. doi: 10.1002/pbc.26974. Epub 2018 Jan 19.

PMID:
29350487
9.

The sentinel lymph node spread determines quantitatively melanoma seeding to non-sentinel lymph nodes and survival.

Ulmer A, Dietz K, Werner-Klein M, Häfner HM, Schulz C, Renner P, Weber F, Breuninger H, Röcken M, Garbe C, Fierlbeck G, Klein CA.

Eur J Cancer. 2018 Mar;91:1-10. doi: 10.1016/j.ejca.2017.12.002. Epub 2018 Jan 6.

PMID:
29316475
10.

How to use neoadjuvant medical treatment to maximize surgery in melanoma.

Amaral T, Tampouri I, Garbe C.

Expert Rev Anticancer Ther. 2018 Feb;18(2):121-130. doi: 10.1080/14737140.2018.1421460. Epub 2018 Jan 3.

PMID:
29271674
11.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C.

Eur J Cancer. 2018 Mar;91:168-170. doi: 10.1016/j.ejca.2017.11.023. Epub 2017 Dec 7. No abstract available.

PMID:
29224903
12.

Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.

Gaiser MR, Skorokhod A, Gransheier D, Weide B, Koch W, Schif B, Enk A, Garbe C, Bauer J.

PLoS One. 2017 Nov 27;12(11):e0188602. doi: 10.1371/journal.pone.0188602. eCollection 2017.

13.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

14.

Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma.

Pereira PL, Krüger K, Hohenstein E, Welke F, Sommer C, Meier F, Eigentler T, Garbe C.

Eur Radiol. 2018 Apr;28(4):1456-1464. doi: 10.1007/s00330-017-5099-y. Epub 2017 Nov 9.

PMID:
29124381
15.

Genomics of Immunotherapy-Associated Hyperprogressors-Letter.

Forschner A, Niessner H, Möller Y, Horak P, Fröhlich M, Warsow G, Stenzinger A, Fröhling S, Glimm H, Klumpp B, Garbe C, Sinnberg T.

Clin Cancer Res. 2017 Oct 15;23(20):6374-6375. doi: 10.1158/1078-0432.CCR-17-1480. No abstract available.

PMID:
29030332
16.

Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP).

Offenmueller S, Leiter U, Bernbeck B, Garbe C, Eigentler T, Borkhardt A, Friedrich Classen C, Corbacioglu S, Dirksen U, Ebetsberger-Dachs G, Heinzerling L, Jorch N, Kuhlen M, Lawlor J, Niggli F, Streiter M, Schneider DT, Brecht I.

Klin Padiatr. 2017 Nov;229(6):322-328. doi: 10.1055/s-0043-118662. Epub 2017 Oct 10.

PMID:
29017184
17.

Safety of shortened infusion times for combined ipilimumab and nivolumab.

Gassenmaier M, Lipp HP, Scheu A, Wagner NB, Kofler L, Mueller A, Doecker D, Eigentler TK, Garbe C, Forschner A.

Cancer Immunol Immunother. 2018 Jan;67(1):135-140. doi: 10.1007/s00262-017-2075-y. Epub 2017 Oct 7.

PMID:
28988363
18.

'Corrigendum to "Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins" [Eur J Cancer 81 (August 2017) 203-205]'.

Spänkuch I, Gassenmaier M, Tampouri I, Noor S, Forschner A, Garbe C, Amaral T.

Eur J Cancer. 2017 Dec;87:221. doi: 10.1016/j.ejca.2017.09.012. Epub 2017 Oct 3. No abstract available.

PMID:
28986136
19.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL.

J Clin Oncol. 2017 Oct 5:JCO2017737379. doi: 10.1200/JCO.2017.73.7379. [Epub ahead of print]

PMID:
28981385
20.

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.

Suciu S, Eggermont AMM, Lorigan P, Kirkwood JM, Markovic SN, Garbe C, Cameron D, Kotapati S, Chen TT, Wheatley K, Ives N, de Schaetzen G, Efendi A, Buyse M.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx133. Review.

PMID:
28922786
21.

Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.

Amaral T, Leiter U, Garbe C.

Rev Endocr Metab Disord. 2017 Dec;18(4):517-532. doi: 10.1007/s11154-017-9433-0. Review.

PMID:
28916903
22.

The need for psycho-oncological support for melanoma patients: Central role of patients' self-evaluation.

Mayer S, Teufel M, Schaeffeler N, Keim U, Garbe C, Eigentler TK, Zipfel S, Forschner A.

Medicine (Baltimore). 2017 Sep;96(37):e7987. doi: 10.1097/MD.0000000000007987.

23.

Immunotherapy in managing metastatic melanoma: which treatment when?

Amaral T, Meraz-Torres F, Garbe C.

Expert Opin Biol Ther. 2017 Dec;17(12):1523-1538. doi: 10.1080/14712598.2017.1378640. Epub 2017 Sep 17. Review.

PMID:
28891339
24.

Durch Pembrolizumab verursachte Hepatitis: Diagnose und Behandlung.

Forschner A, Schraml C, Pierchalla K, Weide B, Eigentler TK, Lauer UM, Garbe C.

J Dtsch Dermatol Ges. 2017 Sep;15(9):933-935. doi: 10.1111/ddg.13037_g. No abstract available.

PMID:
28872244
25.

Pembrolizumab-induced hepatitis: diagnosis and treatment.

Forschner A, Schraml C, Pierchalla K, Weide B, Eigentler TK, Lauer UM, Garbe C.

J Dtsch Dermatol Ges. 2017 Sep;15(9):933-935. doi: 10.1111/ddg.13037. No abstract available.

PMID:
28872228
26.

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.

Seith F, Forschner A, Schmidt H, Pfannenberg C, Gückel B, Nikolaou K, la Fougère C, Garbe C, Schwenzer N.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):95-101. doi: 10.1007/s00259-017-3813-2. Epub 2017 Aug 22.

PMID:
28831583
27.

Reply to 'Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma'.

Amaral T, Garbe C.

Expert Opin Pharmacother. 2017 Oct;18(14):1537. doi: 10.1080/14656566.2017.1367596. Epub 2017 Aug 18. No abstract available.

PMID:
28812387
28.

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C.

Eur J Cancer. 2017 Sep;83:247-257. doi: 10.1016/j.ejca.2017.06.028. Epub 2017 Aug 23. Review.

PMID:
28756137
29.

Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry.

Gassenmaier M, Eigentler TK, Keim U, Goebeler M, Fiedler E, Schuler G, Leiter U, Weide B, Grischke EM, Martus P, Garbe C.

J Invest Dermatol. 2017 Dec;137(12):2570-2577. doi: 10.1016/j.jid.2017.07.006. Epub 2017 Jul 21.

PMID:
28736231
30.

Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study.

Eigentler TK, Leiter U, Häfner HM, Garbe C, Röcken M, Breuninger H.

J Invest Dermatol. 2017 Nov;137(11):2309-2315. doi: 10.1016/j.jid.2017.06.025. Epub 2017 Jul 21.

PMID:
28736229
31.

BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.

Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F.

Clin Cancer Res. 2017 Oct 15;23(20):6203-6214. doi: 10.1158/1078-0432.CCR-17-0098. Epub 2017 Jul 19.

PMID:
28724666
32.

Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients.

Teramoto Y, Keim U, Gesierich A, Schuler G, Fiedler E, Tüting T, Ulrich C, Wollina U, Hassel JC, Gutzmer R, Goerdt S, Zouboulis C, Leiter U, Eigentler TK, Garbe C.

Br J Dermatol. 2018 Feb;178(2):443-451. doi: 10.1111/bjd.15803. Epub 2017 Dec 20.

PMID:
28707317
33.

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.

Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, Garbe C, Wheatley K; International Melanoma Meta-Analysis Collaborative Group (IMMCG).

Eur J Cancer. 2017 Sep;82:171-183. doi: 10.1016/j.ejca.2017.06.006. Epub 2017 Jul 7. Review.

PMID:
28692949
34.

Imaging characteristics of cardiac metastases in patients with malignant melanoma.

Zitzelsberger T, Eigentler TK, Krumm P, Nikolaou K, Garbe C, Gawaz M, Klumpp B.

Cancer Imaging. 2017 Jul 1;17(1):19. doi: 10.1186/s40644-017-0122-8.

35.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C.

Eur J Cancer. 2017 Sep;82:45-55. doi: 10.1016/j.ejca.2017.05.033. Epub 2017 Jun 22.

PMID:
28648698
36.

Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.

Spänkuch I, Gassenmaier M, Tampouri I, Noor S, Forschner A, Garbe C, Amaral T.

Eur J Cancer. 2017 Aug;81:203-205. doi: 10.1016/j.ejca.2017.05.018. Epub 2017 Jun 20. No abstract available. Erratum in: Eur J Cancer. 2017 Dec;87:221.

PMID:
28641200
37.

S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0.

Eigentler TK, Mühlenbein C, Follmann M, Schadendorf D, Garbe C.

J Dtsch Dermatol Ges. 2017 Jun;15(6):e1-e41. doi: 10.1111/ddg.13247. No abstract available.

PMID:
28591444
38.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators.

BMC Cancer. 2017 May 16;17(1):332. doi: 10.1186/s12885-017-3286-5.

39.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP.

Eur J Cancer. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11.

PMID:
28501764
40.

Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany.

Leiter U, Keim U, Eigentler T, Katalinic A, Holleczek B, Martus P, Garbe C.

J Invest Dermatol. 2017 Sep;137(9):1860-1867. doi: 10.1016/j.jid.2017.04.020. Epub 2017 May 6.

PMID:
28487088
41.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176.

42.

Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.

Niessner H, Kosnopfel C, Sinnberg T, Beck D, Krieg K, Wanke I, Lasithiotakis K, Bonin M, Garbe C, Meier F.

Exp Dermatol. 2017 Jul;26(7):598-606. doi: 10.1111/exd.13372.

PMID:
28423208
43.

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.

Kosnopfel C, Sinnberg T, Sauer B, Niessner H, Schmitt A, Makino E, Forschner A, Hailfinger S, Garbe C, Schittek B.

Oncotarget. 2017 May 30;8(22):35761-35775. doi: 10.18632/oncotarget.16204.

44.

Non-melanoma skin cancer: new and future synthetic drug treatments.

Amaral T, Garbe C.

Expert Opin Pharmacother. 2017 May;18(7):689-699. doi: 10.1080/14656566.2017.1316372. Epub 2017 Apr 17. Review.

PMID:
28414587
45.

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, Maio M.

Lancet Oncol. 2017 May;18(5):611-622. doi: 10.1016/S1470-2045(17)30231-0. Epub 2017 Mar 27.

PMID:
28359784
46.

Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis.

Forschner A, Olthof SC, Gückel B, Martus P, Vach W, la Fougère C, Nikolaou K, Keim U, Eigentler TK, Garbe C, Pfannenberg C.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1312-1318. doi: 10.1007/s00259-017-3674-8. Epub 2017 Mar 18.

PMID:
28315947
47.

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K.

Lancet Oncol. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9.

PMID:
28284557
48.

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.

Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, Blank C, Olah J, Bastholt L, Herceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe C.

Eur J Cancer. 2017 Apr;75:313-322. doi: 10.1016/j.ejca.2017.01.012. Epub 2017 Mar 4.

PMID:
28264791
49.

The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.

Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C.

Eur J Cancer. 2017 Mar;73:85-92. doi: 10.1016/j.ejca.2016.12.010. Epub 2017 Feb 3. Review.

PMID:
28169047
50.

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.

Wistuba-Hamprecht K, Martens A, Heubach F, Romano E, Geukes Foppen M, Yuan J, Postow M, Wong P, Mallardo D, Schilling B, Di Giacomo AM, Khammari A, Dreno B, Maio M, Schadendorf D, Ascierto PA, Wolchok JD, Blank CU, Garbe C, Pawelec G, Weide B.

Eur J Cancer. 2017 Mar;73:61-70. doi: 10.1016/j.ejca.2016.12.011. Epub 2017 Feb 4.

Supplemental Content

Support Center